================================================================================
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15 (d) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of Earliest Event Reported): August 13, 2003
Medicis Pharmaceutical Corporation
(Exact Name of Registrant as Specified in Charter)
Delaware 0-18443 52-1574808
(State or Other Jurisdiction (Commission File Number) (IRS Employer
of Incorporation) Identification No.)
8125 North Hayden Road
Scottsdale, Arizona 85258-2463
(Address of Principal (Zip Code)
Executive Offices)
Registrant's telephone number, including area code: (602)808-8800
N/A
---------------------------------------------------------------
(Former Name or Former Address, if Changed Since Last Report)
================================================================================
Item 7. Financial Statements and Exhibits
(a) Financial Statements of Business Acquired.
Not Applicable.
(b) Pro Forma Financial Information.
Not Applicable.
(c) Exhibits.
99.1 Copy of press release, dated August 13, 2003, issued by Medicis
Pharmaceutical Corporation
Item 9. Regulation FD Disclosure
On August 13, 2003, Medicis Pharmaceutical Corporation issued a press
release announcing the expiration and results of the exchange offer for its new
1.5% Contingent Convertible Senior Notes due 2033. A copy of the press release
appears as Exhibit 99.1 to this Current Report and is incorporated herein by
reference.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
Registrant has duly caused this Report to be signed on its behalf by the
undersigned hereunto duly authorized.
MEDICIS PHARMACEUTICAL
CORPORATION
(Registrant)
Date: August 18, 2003 /s/ Mark A. Prygocki, Sr.
-------------------------------
Name: Mark A. Prygocki, Sr.
Title: Executive Vice President,
Chief Financial Officer,
Corporate Secretary and
Treasurer
EXHIBIT INDEX
EXHIBIT
NUMBER DESCRIPTION
------- ----------------------------------------------------------------
99.1 Copy of press release, dated August 13, 2003, issued by Medicis
Pharmaceutical Corporation.